DURHAM, N.C. -- Sufficient sleep has been proven to help keep the body healthy and the mind sharp. But it's not just an issue of logging at least seven hours of Z's.
A new study on sleep patterns suggests that a regular bedtime and wake time are just as important for heart and metabolic health among older adults.
In a study of 1,978 older adults publishing Sept. 21 in the journal Scientific Reports, researchers at Duke Health and the Duke Clinical Research Institute found people with irregular sleep patterns weighed more, had higher blood sugar, higher blood pressure, and a higher projected risk of having a heart attack or stroke within 10 years than those who slept and woke at the same times every day.
Irregular sleepers were also more likely to report depression and stress than regular sleepers, both of which are tied to heart health.
African-Americans had the most irregular sleep patterns compared to participants who were white, Chinese-American or Hispanic, the data showed.
The findings show an association -- not a cause-and-effect relationship -- between sleep regularity and heart and metabolic health.
"From our study, we can't conclude that sleep irregularity results in health risks, or whether health conditions affect sleep," said Jessica Lunsford-Avery, Ph.D., an assistant professor in psychiatry and behavioral sciences and the study's lead author. "Perhaps all of these things are impacting each other."
Still, the data suggest tracking sleep regularity could help identify people at risk of disease, and where health disparities may impact specific groups, such as African Americans.
"Heart disease and diabetes are extremely common in the United States, are extremely costly and also are leading causes of death in this country," she said. "To the extent we can predict individuals at risk for these diseases, we may be able to prevent or delay their onset."
Participants used devices that tracked sleep schedules down to the minute so researchers could learn whether even subtle changes -- going to bed at 10:10 p.m. instead of the usual 10 p.m. -- were linked to the health of participants. Their ages ranged from 54 to 93, and people with diagnosed sleep disorders such as sleep apnea were not included.
The study also tracked the duration of participants' sleep and preferred timing -- whether someone turned in early or was a night owl. According to these measures, people with hypertension tended to sleep more hours, and people with obesity tended to stay up later.
Of all three measures, however, regularity was the best at predicting someone's heart and metabolic disease risk, the researchers found.
As one might expect, irregular sleepers experienced more sleepiness during the day and were less active -- perhaps because they were tired, Lunsford-Avery said.
Researchers plan to conduct more studies over longer periods in hopes of determining how biology causes changes in sleep regularity and vice-versa.
"Perhaps there's something about obesity that disrupts sleep regularity," Lunsford-Avery said. "Or, as some research suggests, perhaps poor sleep interferes with the body's metabolism which can lead to weight gain, and it's a vicious cycle. With more research, we hope to understand what's going on biologically, and perhaps then we could say what's coming first or which is the chicken and which is the egg."
In addition to Lunsford-Avery, study authors include Matthew M. Engelhard, Ann Marie Navar and Scott H. Kollins.
The research was supported by the National Institute of Mental Health (K23 MH108704) and the National Heart, Lung, and Blood Institute, (K01HL13341, N01-HC-95159 through N01-HC-95169, R01 L098433, R24 HL114473), both branches of the National Institutes of Health.
The authors reported several financial disclosures: Lunsford-Avery has received consulting fees from Behavioral Innovations Group; Kollins has received research support or consulting fees from Akili Interactive, Bose, Jazz, KemPharm, Medgenics, Neos, Otsuka, Rhodes, Shire and Sunovion; Navar has received research support or consulting fees from Amgen, Regeneron, Sanofi, Janssen and Amarin.